6.97
Biocryst Pharmaceuticals Inc (BCRX) 最新ニュース
BioCryst to Present at Morgan Stanley Global Healthcare Conference - AOL.com
Biotech Stocks Facing FDA Decision In December 2025 - RTTNews
Why BioCryst (BCRX) Might be Well Poised for a Surge - sharewise.com
Will BioCryst Pharmaceuticals Inc. stock return to pre crisis levelsMarket Sentiment Review & Free High Return Stock Watch Alerts - newser.com
Why BioCryst Pharmaceuticals Inc. stock could benefit from AI revolutionJuly 2025 Spike Watch & Technical Pattern Based Buy Signals - newser.com
BioCryst at Jefferies Conference: Strategic Growth and Acquisitions By Investing.com - Investing.com Canada
BCRX: ORLADEYO growth, Astria acquisition, and Nevenabart launch drive profitability and pipeline momentum - TradingView
Why retail investors pile into BioCryst Pharmaceuticals Inc. stock2025 Market Outlook & Daily Stock Momentum Reports - newser.com
Will BioCryst Pharmaceuticals Inc. stock attract ESG investors2025 Top Decliners & Safe Swing Trade Setups - newser.com
Can BioCryst Pharmaceuticals Inc. stock deliver consistent earnings growth2025 Valuation Update & AI Powered Market Trend Analysis - newser.com
Is BioCryst Pharmaceuticals Inc. stock ready for a breakoutGlobal Markets & Weekly Momentum Picks - newser.com
BioCryst Pharmaceuticals Inc.’s volatility index tracking explainedPortfolio Value Report & Real-Time Volume Analysis Alerts - newser.com
Astria Therapeutics Reports Q3 2025 Results and BioCryst Acquisition - TipRanks
Why Analysts Say the BioCryst Story Is Changing After Astria Therapeutics Acquisition - Yahoo Finance
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - MarketScreener
Is BioCryst Pharmaceuticals Inc. stock bottoming out2025 Analyst Calls & Daily Technical Forecast Reports - newser.com
Will BioCryst Pharmaceuticals Inc. stock maintain growth storyBull Run & Growth-Oriented Investment Plans - newser.com
Trading the Move, Not the Narrative: (BCRX) Edition - news.stocktradersdaily.com
Is BioCryst’s Surging ORLADEYO Sales and Astria Deal Reshaping the Investment Case for BCRX? - Sahm
BioCryst Pharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - 富途牛牛
Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - simplywall.st
BioCryst’s ORLADEYO shows sustained attack reduction in pediatric HAE By Investing.com - Investing.com South Africa
BioCryst’s ORLADEYO shows sustained attack reduction in pediatric HAE - Investing.com
BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat) - GlobeNewswire
Is BioCryst Pharmaceuticals Inc. stock ready for breakoutEarnings Risk Summary & Weekly High Potential Alerts - Fundação Cultural do Pará
BioCryst Pharmaceuticals Shines in Q3 Earnings Call - MSN
Can BioCryst Pharmaceuticals Inc. stock outperform in 2025 bull market2025 Breakouts & Breakdowns & Weekly High Return Forecasts - Fundação Cultural do Pará
What technical models suggest about BioCryst Pharmaceuticals Inc.’s comebackPortfolio Profit Report & Real-Time Buy Zone Alerts - newser.com
When is the best time to exit BioCryst Pharmaceuticals Inc.2025 Major Catalysts & Pattern Based Trade Signal System - newser.com
大文字化:
|
ボリューム (24 時間):